---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105011"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:33:34.758195+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Trevi Q2 net loss $12.3M; positive Phase 2b CORAL results for Haduvio in IPF cough

## Summary
- Haduvio met primary endpoint with 60.2% cough reduction (108 mg BID) vs 16.9% placebo (p<0.0001).
- LCQ Total Score increased 3.4 points (108 mg) and 3.7 points (54 mg); 1.3-point increase is clinically meaningful.
- Completed $115M underwritten offering; cash and securities $203.9M, runway into 2029.
- R&D expenses $9.4M (down from $10.0M); G&A $4.3M (up from $3.3M); net loss $12.3M.
- Plans to request End-of-Phase 2 meeting with FDA in Q4 2025; Phase 3 start expected H1 2026.

## SEC filing metadata
- accession: 0000950170-25-105011
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017025105011/0000950170-25-105011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017025105011/trvi-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105011
- JSON: https://secwatch.observer/filing/0000950170-25-105011.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.